Novel structure compound for resisting monkey pox virus and pox virus and combined application of novel structure compound
Through virtual screening and molecular dynamics simulation technology, new compounds targeting monkeypox and smallpox viruses have been developed, solving the side effects and drug resistance of existing drugs, providing efficient and safe treatment options, suitable for the large-scale epidemic of monkeypox .
Patent Information
- Application Number
- CN202411002477.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing anti-monkeypox virus drugs have serious side effects, drug resistance problems and insufficient supply, making it difficult to use and deal with viral mutations for a long time.
Through virtual screening technology, high-affinity compounds were screened based on the structure of VP37, and novel compounds were developed to inhibit the replication of monkeypox and smallpox viruses.
It significantly reduces drug side effects, improves the targeting and therapeutic effect of targeting viruses, extends the use period of drugs, reduces the risk of drug resistance, and provides a reliable treatment plan for the large-scale epidemic of monkeypox.
Smart Images

Figure CN118930542A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmacy and virus infection drugs, and in particular relates to a compound for resisting monkeypox virus and smallpox virus and application thereof. Background Art
[0003] Monkeypox, a zoonotic infectious disease caused by monkeypox virus (MPXV), has historically been prevalent in East Africa, Central Africa and West Africa. Monkeypox virus is classified in the genus Orthopoxvirus of the Poxviridae family. It is mainly transmitted from person to person through direct contact with the infectious parts of an infected person, such as the skin, mouth or genitals. It is not yet certain whether the virus can also be transmitted between animals, but it is known that people can be infected through contact with contaminated objects. The incubation period of the virus ranges from 1 day to 21 days, and symptoms usually last for 2 to 4 weeks. Its typical symptoms include rash, fever, sore throat, headache and muscle aches. In some severe cases, it is even life-threatening.
[0004] At present, the treatment strategy for monkeypox virus is mainly to use drugs for treating smallpox, such as Tecovirimat (also known as ST-246 or Tecovirimat), for emergency treatment. In the past two years, researchers have conducted a detailed analysis of the structure of monkeypox virus. Monkeypox virus appears brick-shaped or oval under an electron microscope, with a size of about 200nm×250nm, a protein envelope, and virus particles including structural proteins and non-structural proteins. Among them, ST-246 (Tecovirimat) as a drug against smallpox virus has been proven to be an inhibitor of the F13L protein of smallpox virus and has been approved by the US FDA for clinical use.
[0005] The existing technology is to use known anti-monkeypox virus drugs for treatment. These drugs fight the virus by inhibiting viral replication or enhancing the human immune system. For example, ribavirin, famciclovir, etc., as broad-spectrum antiviral drugs, can inhibit the activity of monkeypox virus. Although non-steroidal anti-inflammatory drugs such as acetaminophen and ibuprofen cannot directly inhibit the occurrence of the virus, they can relieve symptoms such as fever and pain caused by monkeypox virus and improve patient comfort. Although the above-mentioned drugs have a certain effect in fighting monkeypox virus, they cannot be taken for a long time and have strong side effects, such as gastrointestinal reactions and abnormal liver function. At the same time, as the virus continues to mutate, drug resistance will appear. The key is that during the outbreak of monkeypox virus, the supply of a single drug will be affected, resulting in most people having no medicine to treat and no medicine to save them.
[0006] Through the above analysis, the problems and defects of the prior art are as follows:
[0007] 1) Existing drugs have certain efficacy in combating monkeypox virus, but they cannot be taken for a long time and have strong side effects, such as gastrointestinal reactions and abnormal liver function.
[0008] 2) As the virus continues to mutate, drug resistance will emerge.
[0009] 3) During a monkeypox virus outbreak, the supply of a single drug will be affected, resulting in a large portion of the population being left without access to medication and being unable to be cured. Summary of the invention
[0010] In view of the problems existing in the prior art, the present invention provides a compound capable of resisting monkeypox virus and smallpox virus and application thereof.
[0011] The present invention is achieved in that a method for screening compounds against monkeypox virus and smallpox virus comprises:
[0012] Step 1, screening docking system;
[0013] Step 2, collecting active compounds through DrugBank database;
[0014] Step 3, molecular docking screening was performed using AutoDock Vina software;
[0015] Step 4, comparing the scores with those of the control group compounds;
[0016] Step 5, perform molecular dynamics simulation and analysis;
[0017] Step 6: Calculate the binding energy and analyze and compare.
[0018] Furthermore, the compounds against monkeypox virus and smallpox virus were screened based on the VP37 protein structure to obtain the clinical application of compound formula 2, with an average molecular weight of 557.60Da and molecular formula: C 31 H 29 F2N5O3, its characteristic structure is:
[0019]
[0020] Furthermore, the compounds against monkeypox virus and smallpox virus were screened based on the VP37 protein structure to obtain the clinical application of compound formula 3, with an average molecular weight of 603.525Da and molecular formula: C 31 H 29 The characteristic structure of F2N5O3 is:
[0021]
[0022] Furthermore, the compound of Formula 2 and the compound of Formula 3 include a pharmaceutically acceptable carrier.
[0023] Furthermore, the combined use of compounds against monkeypox virus and smallpox virus includes compounds of Formula 2 and Formula 3 including a pharmaceutically acceptable carrier.
[0024] Furthermore, the use of compounds against monkeypox virus and smallpox virus includes therapeutic applications in patients with smallpox and monkeypox.
[0025] The present invention also provides a method for preparing a compound resistant to monkeypox virus and smallpox virus, the method comprising the following steps:
[0026] Step A: Collecting compounds with potential activity through DrugBank database;
[0027] Step B: Use AutoDock Vina software to perform molecular docking screening between the collected compounds and VP37 protein to determine candidate compounds with good docking scores;
[0028] Step C: Perform molecular dynamics simulation on the screened candidate compounds to evaluate their stability and interaction with VP37 protein;
[0029] Step D: Analyze and compare the binding strength of each candidate compound with the VP37 protein through binding energy calculation, and select the best compound as the compound against monkeypox virus and smallpox virus.
[0030] The present invention also provides a method for preparing a compound resistant to monkeypox virus and smallpox virus based on virtual screening technology, characterized in that the method comprises the following steps:
[0031] Step A: Establishing a docking system including VP37 protein and performing necessary pretreatment and optimization;
[0032] Step B: Using the DrugBank database or similar data sources, collect compounds related to virus inhibition or treatment and construct a compound library;
[0033] Step C: Virtual screening of compounds in the compound library using molecular docking software to identify candidate compounds with high affinity to the VP37 protein;
[0034] Step D: Conducting further in vitro or in vivo experimental verification on the screened candidate compounds to determine their actual effects against monkeypox virus and smallpox virus;
[0035] Step E: Based on the experimental verification results, optimize the structure and performance of the compound to prepare a highly effective and safe compound against monkeypox virus and smallpox virus.
[0036] The present invention also provides a method for preparing a compound containing a pharmaceutically acceptable carrier that is resistant to monkeypox virus and smallpox virus, characterized in that the method comprises the following steps:
[0037] Step A: preparing a compound resistant to monkeypox virus and smallpox virus according to the steps of preparation method 1 or preparation method 2;
[0038] Step B: selecting a pharmaceutically acceptable carrier, such as microcrystalline cellulose, lactose, magnesium stearate, etc., to improve the solubility, stability or taste of the compound;
[0039] Step C: mixing the anti-monkeypox virus and smallpox virus compound with a carrier, and preparing a pharmaceutical preparation suitable for clinical use, such as tablets, capsules, oral liquids, etc., through a formulation technology;
[0040] Step D: Conduct quality control and stability testing on the prepared drug preparation to ensure that it meets relevant standards and requirements.
[0041] In combination with the above technical solutions and the technical problems solved, the advantages and positive effects of the technical solutions to be protected by the present invention are as follows:
[0042] First, the present invention obtains a compound with anti-VP37 protease activity through a virtual screening method, which will provide a new method for treating monkeypox virus. This method will overcome the limitations of the above-mentioned prior art, for example, by targeting different protease activities, reducing the drug resistance of the virus to drugs, and at the same time, through precise molecular design, it will reduce the side effects of drugs.
[0043] The present invention found that the binding energy of the compound is better than ST-246. The compound has the advantages of low toxicity, strong effect, safety and effectiveness, strong drugability, etc., which has opened up a new way to treat the new coronavirus and smallpox virus, and has important strategic significance, social value, economic value and broad application prospects. The compound in the present invention is a clinical drug for the treatment of headaches, with relatively complete biological metabolism, drugability and preparation process, and can cope with the large-scale epidemic of monkeypox virus.
[0044] The compounds provided by the present invention are all obtained based on molecular technology of protein structure, and are verified by molecular docking method, molecular dynamics simulation and protein structure virtual screening technology. The core innovations are: 1) the accuracy and specificity of the structure are ensured by advanced molecular technology; 2) the compounds described have specific IUPAC nomenclature and structure, and have specific activities and applications in the biological or medical fields; 3) new compound structures are provided as candidates for drugs or research tools, expanding the existing compound library.
[0045] Second, as auxiliary evidence of the inventiveness of the claims of the present invention, it is also reflected in the following important aspects:
[0046] (1) The expected benefits and commercial value of the technical solution of the present invention after transformation are:
[0047] The anti-monkeypox virus and smallpox virus compounds provided by the present invention, if clinically verified to be effective, will be expected to occupy an important market share and bring considerable economic benefits to pharmaceutical companies. Secondly, the technical solution can also be used as a research tool to promote scientific research progress in the field of antiviral drugs, thereby promoting innovation and development of the entire pharmaceutical industry.
[0048] (2) The technical solution of the present invention fills the technical gap in the industry at home and abroad:
[0049] The technical solution of the present invention fills the technical gap in the field of drug research and development against monkeypox virus and smallpox virus at home and abroad. At present, the treatment strategies for these viruses are limited, and there are problems such as large side effects and easy drug resistance. The present invention uses a unique virtual screening method to discover new compounds with high affinity to VP37 protein, providing new ideas and directions for the development of antiviral drugs.
[0050] (3) Whether the technical solution of the present invention overcomes technical prejudice:
[0051] The present invention overcomes the technical drawbacks of the original drug discovery, firstly expands the therapeutic range of the drug for treating migraine, and its biological metabolism, drugability and preparation process are relatively complete, which can cope with the large-scale epidemic of monkeypox virus. This discovery breaks the shackles of traditional treatment strategies, demonstrates a new antiviral drug treatment approach, and opens up a new path for the treatment of monkeypox and smallpox virus.
[0052] Third, the present invention proposes a solution based on virtual screening of VP37 protein structure to address the problems of poor targeting, poor therapeutic effect and significant side effects in the development of existing anti-monkeypox virus and smallpox virus drugs. Traditional drug development methods are inefficient, and in practical applications, they often face insufficient inhibitory effects of drugs on viral targets, resulting in unsatisfactory treatment effects for patients. In addition, existing drugs have low selectivity for specific proteins of monkeypox virus and smallpox virus (such as VP37), which can easily cause side effects and affect the overall health and treatment compliance of patients.
[0053] By adopting a virtual screening method based on the VP37 protein structure, the present invention significantly improves the screening efficiency of anti-monkeypox virus and smallpox virus drugs. Combined with molecular dynamics simulation technology, candidate compounds (compound formula 2 and compound formula 3) can be quickly identified and optimized, thereby shortening the drug development cycle. This method not only improves the accuracy of drug screening, but also significantly reduces the waste of experimental resources, improves the overall efficiency of drug development, and enables researchers to find effective antiviral compounds faster.
[0054] The present invention precisely designs and optimizes the compound formula 2 (molecular formula: C 31 H 29 F2N5O3, molecular weight: 557.60Da) and compound formula 3 (molecular formula: C 31 H 29 F2N5O3, molecular weight: 603.525Da), ensures its high efficiency and safety in the treatment of monkeypox virus and smallpox virus. These compounds have high targeting and can specifically inhibit or block VP37 protein to prevent viral replication. Compared with traditional drugs, the novel structural compounds of the present invention show significant advantages in efficacy and safety, reduce side effects during treatment, and improve patients' treatment compliance and quality of life.
[0055] The present invention has made significant technological progress in the field of drug development against monkeypox virus and smallpox virus. First, through advanced virtual screening and molecular dynamics simulation technology, the efficiency and accuracy of drug screening are improved, and the process of new drug development is significantly accelerated. Secondly, two highly effective and safe compounds (Compound Formula 2 and Compound Formula 3) are developed, which can specifically inhibit or block VP37 protein, significantly improving the therapeutic effect. Finally, through pharmaceutically acceptable carriers, the stability and bioavailability of the drug are enhanced to ensure its effectiveness and safety in clinical applications. These technological advances provide strong support for the fight against monkeypox virus and smallpox virus, and promote technological innovation and development in the field of antiviral drug development. BRIEF DESCRIPTION OF THE DRAWINGS
[0056] Figure 1 It is a flow chart of a method for screening compounds against monkeypox virus and smallpox virus provided in an embodiment of the present invention;
[0057] Figure 2 is a 2D molecular diagram of the molecule of Chemical Formula 1 provided in an embodiment of the present invention;
[0058] Figure 3 is a 2D molecular diagram of the molecule of Chemical Formula 2 provided in an embodiment of the present invention;
[0059] Figure 4 is a 2D molecular diagram of the molecule of Chemical Formula 3 provided in an embodiment of the present invention;
[0060] Figure 5 The protein structure diagrams generated by the embodiments of the present invention are shown in Figure 1. (a) represents the front view of the three protein structures, and (b) represents the top view of the three proteins. The blue represents the docking center.
[0061] Figure 6Schematic diagrams of docking conformations of compounds of Formula 1, 2 and 3 provided in the embodiments of the present invention; (a) represents the docking site of compound Formula 2. (b) represents the docking site of compound Formula 3. (c) represents the docking site of compound Formula 1;
[0062] Figure 7 RMSD, RMSF, H-bond and Rg images of Chemical Formula 2 provided in an embodiment of the present invention are compared with those of Chemical Formula 1;
[0063] Figure 8 RMSD, RMSF, H-bond and Rg images of Chemical Formula 3 provided in an embodiment of the present invention are compared with those of Chemical Formula 1;
[0064] Fig. 9 It is a diagram of the calculation results of the biological activity, free energy and docking energy of Chemical Formulas 1, 2 and 3 provided in the embodiments of the present invention. DETAILED DESCRIPTION
[0065] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0066] like Figure 1 As shown, the screening of a compound against monkeypox virus and smallpox virus provided in an embodiment of the present invention comprises the following steps:
[0067] S101, screening docking system;
[0068] S102, collecting active compounds through DrugBank database;
[0069] S103, molecular docking screening by AutoDock Vina software;
[0070] S104, comparison of scores with control compounds;
[0071] S105, molecular dynamics simulation and analysis;
[0072] S106, calculate the binding energy, and analyze and compare.
[0073] The anti-monkeypox virus and smallpox virus compound provided in the embodiment of the present invention is based on the clinical application of the compound formula 2 obtained by virtual screening of the VP37 protein structure, with an average molecular weight of 557.60Da and a molecular formula of C 31 H 29 F2N5O3, its characteristic structure is:
[0074]
[0075] The anti-monkeypox virus and smallpox virus compound provided in the embodiment of the present invention is based on the virtual screening of the VP37 protein structure to obtain the clinical application of compound formula 3, with an average molecular weight of 603.525Da and a molecular formula of C 31 H 29 The characteristic structure of F2N5O3 is:
[0076]
[0077] The compounds of Formula 2 and Formula 3 provided in the embodiments of the present invention include a pharmaceutically acceptable carrier.
[0078] The combined use of the anti-monkeypox virus and smallpox virus compound provided in the embodiment of the present invention includes the compound of formula 2 and chemical formula 3 including a pharmaceutically acceptable carrier.
[0079] The application of the anti-monkeypox virus and smallpox virus compound provided in the embodiment of the present invention includes the treatment of smallpox patients and monkeypox patients.
[0080] The present invention is specifically implemented:
[0081] Figure 2 is a 2D molecular diagram of the molecule of Chemical Formula 1 provided in Example 1 of the present invention;
[0082] Figure 3 is a 2D molecular diagram of the molecule of Chemical Formula 2 provided in an embodiment of the present invention;
[0083] Figure 4 is a 2D molecular diagram of the molecule of Chemical Formula 3 provided in an embodiment of the present invention;
[0084] Figure 5 The protein structure diagrams generated by the embodiments of the present invention are shown in Figure 1. (a) represents the front view of the three protein structures, and (b) represents the top view of the three proteins. The blue represents the docking center.
[0085] Figure 6 Schematic diagrams of docking conformations of compounds of Formula 1, 2 and 3 provided in the embodiments of the present invention; (a) represents the docking site of compound Formula 2. (b) represents the docking site of compound Formula 3. (c) represents the docking site of compound Formula 1;
[0086] Figure 7 RMSD, RMSF, H-bond and Rg images of Chemical Formula 2 provided in an embodiment of the present invention are compared with those of Chemical Formula 1;
[0087] Figure 8 RMSD, RMSF, H-bond and Rg images of Chemical Formula 3 provided in an embodiment of the present invention are compared with those of Chemical Formula 1;
[0088] Fig. 9 It is a diagram of the calculation results of the biological activity, free energy and docking energy of Chemical Formulas 1, 2 and 3 provided in the embodiments of the present invention.
[0089] The therapeutic application of the compound formula 2 provided in the present invention based on structure virtual screening is superior to the existing compound ST-246. The compound formula 2 has an IUPAC name: 2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(2R)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide. The canonial SMILES format is as follows:
[0090] O=C(CN1C(=O)C2(CCCC2)NC[C@H]1c1cc(F)cc(F)c1)Nc1ccc2c(c1)C[C@@]1(C2)C(=O)Nc2ncccc21,
[0091] Its physical and chemical properties are as follows: average molecular weight is 557.60, molecular formula: C 31 H 29 F2N5O3,
[0092] LogP=2.85, logS=-4.6, pKa=6.68, Polar Surface
[0093] Its characteristic structure is Figure 3 shown.
[0094] The therapeutic application of the compound formula 3 provided in the present invention based on structure virtual screening is superior to the existing compound ST-246. Wherein the compound formula 3, its IUPAC name is:
[0095] (6S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2'-oxo-1',2',5,
[0096] 7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide. The canonial SMILES format is as follows:
[0097] CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F,
[0098] Its physical and chemical properties are as follows: average molecular weight is 603.525, molecular formula: C 31 H 29 F2N5O3, LogP=3.62, logS=-4.4, pKa=3.83, Polar Surface
[0099] In the present invention, all protein structures and compound structures are from the RCSB PDB database, using Gromacsv2022 and AmberTools 23 to prepare receptor modules and repair missing atoms.
[0100] The purpose of the present invention is to provide a compound that has a significant inhibitory or blocking effect on the VP37 protein and also has stable pharmaceutical characteristics.
[0101] The method for preparing a novel structural compound for resisting monkeypox virus provided in an embodiment of the present invention comprises the following steps:
[0102] Step 1: Providing starting materials
[0103] The starting material used in the present invention is an organic compound with suitable reactivity, and its structure is carefully selected so as to be converted into the target compound through the subsequent chemical reaction steps. The specific starting material can be selected according to actual needs, but it must be ensured that it can obtain the target compound with the molecular formula of C30H44O5 through the subsequent reaction.
[0104] Step 2: Chemical Reaction Process
[0105] The starting materials are gradually converted into the target compound through a series of carefully designed chemical reaction steps, including but not limited to oxidation, reduction, addition, elimination, etc. In these reaction steps, the reaction conditions, such as temperature, pressure, reaction time, etc., are strictly controlled to ensure the smooth progress of the reaction and the formation of the target product.
[0106] Step 3: Use specific catalysts and solvents
[0107] In order to improve the reaction efficiency and selectivity and ensure the yield and purity of the target compound, the present invention adopts a specific catalyst or solvent in the chemical reaction step. These catalysts or solvents can effectively promote the reaction and inhibit the occurrence of side reactions, thereby improving the purity and yield of the target compound.
[0108] Step 4: Isolation and purification
[0109] After the reaction is completed, the reaction product is separated and purified. This step includes but is not limited to extraction, crystallization, recrystallization, chromatographic separation and other operations to remove impurities and obtain a novel structure compound of anti-monkeypox virus with a purity that meets the requirements of medical application. In the separation and purification process, the operating conditions also need to be strictly controlled to ensure the purity and yield of the target compound.
[0110] Then, computer-aided drug design technology was used to conduct virtual docking simulation between the target compound and VP37 protein based on the protein structure molecular docking method;
[0111] Based on the docking simulation results, design or select candidate compounds that can form stable binding with VP37 protein;
[0112] Candidate compounds are prepared and their inhibitory or blocking effects on VP37 protein are verified through experiments, thereby obtaining novel structural compounds against monkeypox virus.
[0113] The present invention constructs an in vitro molecular target model, verifies the docking center, performs molecular dynamics experiments and calculates binding energy, and finds that Formula 2 and Formula 3 have binding activities superior to those of the control group and minimum binding energy. Therefore, the compound has the ability to treat monkeypox virus VP37.
[0114] The software parameter settings adopted in the present invention are all conventional settings.
[0115] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0116] In order to prove the creativity and technical value of the technical solution of the present invention, this section provides application examples of the claimed technical solution on specific products or related technologies.
[0117] Example 1 Molecular docking experiment
[0118] Since there is no VP37 protein structure in the PDB database, this project uses three commonly used protein generation methods: AlphaFold2, Swiss-model and I-TASSER to generate docking proteins. Then, according to the VP37 gene sequence of MPXV_USA_2022_MA001, the three protein structures were obtained by inputting them into their web pages.
[0119] like Figure 4 As shown in the figure, combined with the comprehensive analysis of protein stability and docking site, the docking region structure of AlphaFold2 has a high confidence interval, and relatively speaking, the confidence interval is high. Therefore, the AlphaFold2 structure was selected as the docking protein.
[0120] The GHECOM website was used to analyze the docking pockets of protein structural modules. In the docking box, the network center is defined as the docking center. The ligand small molecule is docked using the Vina mode. All other parameters are the default values in the docking module in AutoDock Vina.
[0121] In view of the rapid development of monkeypox virus, in this study, compounds in the Drug Bank database were used for rapid molecular docking and it was found that the scoring functions of compound formula 2 and compound formula 3 were lower than those of the reference compound ST-246.
[0122] The results are as follows Figure 5 It represents the docking image of compound 2 and compound 3.
[0123] 1. Specific application fields or related products of the present invention.
[0124] The specific chemical formula 2 of the present invention is ATOGEPANT, which is used as an oral drug for treating migraine. The present invention expands the clinical application of the drug.
[0125] The specific chemical formula 3 in the present invention is MK-3207, which is the earliest candidate drug for oral application for treating migraine. However, it is no longer in clinical use because the clinical results did not meet the expected standards.
[0126] 2. Relevant evidence of the technical effects obtained by the embodiments of the present invention.
[0127] Example 1 Molecular dynamics experiment
[0128] VP37 protein and compounds were all based on AMBERff19SB and GAFF positions, in which the system adopted the TIP3P water model with the edge The solution was solvated using a cubic water box. Periodic boundary conditions (PBC) were used and 0.15 M NaCl was used to neutralize the net charge. The van der Waals interactions were calculated using the LJ 12-6 potential with a cutoff of The long-range electrostatic forces are handled using the PME algorithm. The covalent bonds involving hydrogen atoms are constrained using the SHAKE algorithm. To eliminate unfavorable interatomic contacts, the heavy atoms are first Constraints were applied, and 2500 steps of steepest descent and 2500 steps of conjugate gradient energy minimization were performed. The entire system was then relaxed and 10,000 steps of steepest descent and 10,000 steps of conjugate gradient energy minimization were performed. The system was then gradually heated to 300K using a 20ps NVT simulation. This was followed by a two-step equilibrium phase, first a 200ps constrained heavy atom NPT simulation, followed by a 500ps unconstrained NVT simulation. The temperature was controlled at 300K using a Berendsen thermal bath, and the pressure was controlled at 1atm using a Monte Carlo pressure bath. The coupling constant and relaxation time were both 1ps. Finally, a 100ns NVT simulation was performed with an integration time step of 2fs.
[0129] The results are shown in the figure. According to the 100ns molecular dynamics simulation, the RMSD value calculated can indicate the stability of the interaction between the compound and the protein. At the same time, the three images of Rg, RMSF, and H-bond were verified to prove that the simulation system is stable and that the compound exhibits strong inhibitory properties in the protein system.
[0130] The embodiments of the present invention have achieved some positive effects during the development or use process, and indeed have great advantages over the prior art. The following content is described in conjunction with data, charts, etc. of the test process.
[0131] Example 2MM / PBSA binding energy test
[0132] Binding free energy calculations were performed on the last stable 20 ns snapshot of the molecular dynamics trajectory using the MM / PBSA method in AmberTools 22. For every 100 frames, the binding free energies of the receptor, ligand, and complex were calculated using the “single trajectory” approach.
[0133] The total binding free energy was calculated according to the following formula:
[0134] ΔG bind =ΔG complex -(ΔG receptor +ΔG ligand )
[0135] =ΔE vdw +ΔE ele +ΔG PB +ΔG SA -TΔS
[0136] Among them, ΔG complex , ΔG receptor and ΔG ligand represent the free energy of the complex, receptor, and ligand, respectively; ΔE vdw , ΔE ele , ΔG PB and ΔG SAare the polar and nonpolar parts of van der Waals energy, electrostatic energy and desolvation free energy respectively; TΔS represents the conformational entropy contribution at temperature T. ΔG PB The term is determined by the PB model, and ΔG SA Then ΔG SA =γ×SASA+β, where SASA is the solvent accessible surface area, and the values of constants γ and β are and 0.92 kcal·mol -1 The molecular surface area is given by the radius The results are given by Figure 8 express.
[0137] Example 3 Based on large-scale prediction activity test
[0138] The stable conformation in AMBER docking was used to predict the binding energy of the stable structure using the PRODIGY-LIG website. Then, the inhibitory activity in the stable state was obtained using the following formula (1). R is the room temperature constant of 8.31432×103N mkmol -1 K -1 , T is room temperature 25℃ and the standard temperature is 300K.
[0139] RTIn(K D )=ΔF bind
[0140] According to the content displayed on the webpage, the binding energy of compound ST-246 is -8.07kcal / mol, which is lower than the binding energy of compound formula 2, which is -9.91kcal / mol. According to the predicted biological activity calculated by the formula, the activity of compound formula 2 (0.0597μM) is higher than the activity of compound ST-246 (1.31μM). At the same time, the binding energy of compound formula 3 is -9.59kcal / mol, and the compound activity of compound formula 3 is 0.102μM, which is also higher than the activity of reference compound ST-246 (1.31μM). See for details Fig. 9 .
[0141] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention and within the spirit and principle of the present invention should be covered by the protection scope of the present invention.
Claims
1. A compound that is resistant to monkeypox virus and smallpox virus, It is characterized in that Compounds against monkeypox virus and smallpox virus are clinically applied based on virtual screening of VP37 protein structure, with an average molecular weight of 557.60Da and molecular formula: C 31 H 29 F 2 N 5 O 3 , its characteristic structure is:
2. The compound as claimed in claim 1 that is resistant to monkeypox virus and smallpox virus, It is characterized in that Compounds against monkeypox virus and smallpox virus are clinically applied based on virtual screening of VP37 protein structure, with an average molecular weight of 603.525Da and molecular formula: C 31 H 29 F 2 N 5 O 3 Its characteristic structure is:
3. The compound against monkeypox virus and smallpox virus according to any one of claims 1 or 2, It is characterized in that The compound of Formula 2 and the compound of Formula 3 include a pharmaceutically acceptable carrier.
4. A method for preparing a compound that is resistant to monkeypox virus and smallpox virus, It is characterized in that The method comprises the following steps: Step A: Collecting compounds with potential activity through DrugBank database; Step B: Use AutoDock Vina software to perform molecular docking screening between the collected compounds and VP37 protein to determine candidate compounds with good docking scores; Step C: Perform molecular dynamics simulation on the screened candidate compounds to evaluate their stability and interaction with VP37 protein; Step D: Analyze and compare the binding strength of each candidate compound with the VP37 protein through binding energy calculation, and select the best compound as the compound against monkeypox virus and smallpox virus.
5. A method for preparing a compound against monkeypox virus and smallpox virus based on virtual screening technology, It is characterized in that The method comprises the following steps: Step A: Establishing a docking system including VP37 protein and performing necessary pretreatment and optimization; Step B: Using the DrugBank database or similar data sources, collect compounds related to virus inhibition or treatment and construct a compound library; Step C: Virtual screening of compounds in the compound library using molecular docking software to identify candidate compounds with high affinity to the VP37 protein; Step D: Conducting further in vitro or in vivo experimental verification on the screened candidate compounds to determine their actual effects against monkeypox virus and smallpox virus; Step E: Based on the experimental verification results, optimize the structure and performance of the compound to prepare a highly effective and safe compound against monkeypox virus and smallpox virus.
6. A method for preparing a compound that is resistant to monkeypox virus and smallpox virus and contains a pharmaceutically acceptable carrier, It is characterized in that The method comprises the following steps: Step A: preparing a compound resistant to monkeypox virus and smallpox virus according to the steps of preparation method 1 or preparation method 2; Step B: selecting a pharmaceutically acceptable carrier, including microcrystalline cellulose, lactose, and magnesium stearate, to improve the solubility, stability, or taste of the compound; Step C: mixing the compound against monkeypox virus and smallpox virus with a carrier, and preparing a pharmaceutical preparation suitable for clinical use by a formulation technology; Step D: Conduct quality control and stability testing on the prepared drug preparation to ensure that it meets relevant standards and requirements.
7. A combined use of the compound against monkeypox virus and smallpox virus as claimed in claim 1, It is characterized in that The combined use of compounds against monkeypox virus and smallpox virus includes compounds of Formula 2 and Formula 3 and a pharmaceutically acceptable carrier.
8. Use of the compound against monkeypox virus and smallpox virus according to any one of claims 1 to 3, It is characterized in that The use of compounds against monkeypox virus and smallpox virus includes therapeutic applications in patients with smallpox and monkeypox.
Citation Information
Patent Citations
Substituted spirocyclic CGRP receptor antagonists
CN101443323A
Methods of treating lung injury with CGRP inhibitors
CN115697378A
Preparation and application of spiro compound with antihypertensive effect
CN116874485A
Anti-monkey pox virus novel structure compound composition and application thereof
CN117603293A
Diketopiperazine alkaloid compound for resisting novel coronavirus and application of diketopiperazine alkaloid compound
CN117659052A
